RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $32
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
RBC Capital analyst Lisa Walter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and raises the price target from $26 to $32.
RBC Capital analyst Lisa Walter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and raises the price target from $26 to $32.